Background: Non-completion of a prescribed course of treatment occurs in 20–60% of individuals diagnosed with borderline personality disorder (BPD). While symptom severity, personality traits and environmental factors have been implicated as predictors of treatment non-completion (TNC), there have been no studies of neuropsychological predictors in this population. Methods: From a randomized controlled trial, a subsample of 31, unmedicated outpatients diagnosed with BPD with recent self-injurious behavior was assessed on 5 neuropsychological domains. Patients were also assessed for general IQ, demographic and other salient clinical variables. Patients were randomized to one of four treatment conditions, which lasted up to 1 year. Number of weeks in treatment (WIT) up to 1 year was utilized as the index of TNC. Results: Thirty-three percent of the subsample (n = 12) did not complete 1 year of treatment. However, more WIT were predicted by better baseline executive control (Trails B; p < 0.01) and visual memory performance (Benton visual retention; p < 0.001); other neuropsychological domains did not predict WIT. Conclusion: In the treatment of outpatients with BPD, better executive control and visual memory performance predict more WIT. Assessing and addressing these neurocognitive factors in treatment may reduce TNC in this high-risk population.

Keywords:
Borderline personality disorder, Neuropsychology, Treatment retention, Treatment completion, Treatment adherence, Psychotherapy, Executive function, Memory, Executive control
1.
Horesh N, Sever J, Apter A: A comparison of life events between suicidal adolescents with major depression and borderline personality disorder. Compr Psychiatry 2003;44:277–283.
2.
Lenzenweger MF, Lane MC, Loranger AW, Kessler RC: DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007;62:553–564.
3.
Chiesa M, Sharp R, Fonagy P: Clinical associations of deliberate self-injury and its impact on the outcome of community-based and long-term inpatient treatment for personality disorder. Psychother Psychosom 2011;80:100–109.
4.
Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C: Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2006;1: CD005652.
5.
Oldham JM: Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. Arlington, American Psychiatric Association, 2005.
6.
Sneed JR, Fertuck EA, Kanellopoeulos D, Culang ME: Borderline personality disorder; in Sturmey P, Hersen M (eds): Handbook of Evidence-Based Practice in Clinical Psychology. Hoboken, Wiley, in press.
7.
Gabbard GO: Do all roads lead to Rome? New findings on borderline personality disorder. Am J Psychiatry 2007;164:853–855.
8.
Feurino L III, Silk KR: State of the art in the pharmacologic treatment of borderline personality disorder. Curr Psychiatry Rep 2011;13:69–75.
9.
McMurran M, Huband N, Overton E: Non-completion of personality disorder treatments: a systematic review of correlates, consequences, and interventions. Clin Psychol Rev 2010;30:277–287.
10.
Linehan MM: Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York, Guilford Press, 1993.
11.
Allen DM: Techniques for reducing therapy-interfering behavior in patients with borderline personality disorder. Similarities in four diverse treatment paradigms. J Psychother Pract Res 1997;6:25–35.
12.
Clarkin JF, Yeomans FE, Kernberg OF: Psychotherapy for Borderline Personality: Focusing on Object Relations, ed 1. Washington, American Psychiatric Press, 2006.
13.
Nigg JT, Silk KR, Stavro G, Miller T: Disinhibition and borderline personality disorder. Dev Psychopathol 2005;17:1129–1149.
14.
Fertuck EA, Lenzenweger MF, Clarkin JF, Hoermann S, Stanley B: Executive neurocognition, memory systems, and borderline personality disorder. Clin Psychol Rev 2006;26:346–375.
15.
Ruocco AC: The neuropsychology of borderline personality disorder: a meta-analysis and review. Psychiatry Res 2005;137:191–202.
16.
Posner MI, Rothbart MK, Vizueta N, Levy KN, Evans DE, Clarkin JF: Attentional mechanisms of borderline personality disorder. Proc Natl Acad Sci USA 2002;99:16366–16370.
17.
Fertuck EA, Marsano-Jozefowicz S, Stanley B, Tryon WW, Oquendo M, Mann JJ, Keilp JG: The impact of borderline personality disorder and anxiety on neuropsychological performance in major depression. J Pers Disord 2006;20:55–70.
18.
Aharonovich E, Hasin DS, Brooks AC, Liu X, Bisaga A, Nunes EV: Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend 2006;81:313–322.
19.
First MB, Spitzer RL, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV Axis I Disorders – Patient Edition: SCID-I/P. Washington, American Psychiatric Press, 1996.
20.
Maffei C, Fossati A, Agostoni I, Barraco A, Bagnato M, Deborah D, Namia C, Novella L, Petrachi M: Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. J Pers Disord 1997;11:279–284.
21.
Mangiaracina J, Simon MJ: Comparison of the PPVT-R and WAIS-R in state hospital psychiatric patients. J Clin Psychol 1986;42:817–820.
22.
Grant DA, Berg EA: A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem. J Exp Psychol 1948;38:404–411.
23.
Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1985.
24.
Buschke H, Fuld PA: Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;24:1019–1025.
25.
Sivan AB: Benton Visual Retention Test, ed 5. San Antonio, Psychological Corporation, 1992.
26.
Cornblatt BA, Keilp JG: Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994;20:31–46.
27.
Keilp JG, Sackeim HA, Mann JJ: Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res 2005;135:191–201.
28.
MacLeod CM: Half a century of research on the Stroop effect: an integrative review. Psychol Bull 1991;109:163–203.
29.
Baddeley AD: A three minute reasoning test based on grammatical transformations. Psychon Sci 1968;10:1019–1025.
30.
Cohen JD, Forman SD, Braver TS, Casey BJ, Servan-Schreiber D, Noll DC: Activation of prefrontal cortex in a non-spatial working memory task with functional MRI. Hum Brain Map 1994;1:293–304.
31.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
32.
Oldham JM, Bender DS, Skodol AE, Dyck IR, Sanislow CA, Yen S, Grilo CM, Shea MT, Zanarini MC, Gunderson EJ, McGlashan TH: Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder. J Psychiatr Pract 2004;10:156–161.
33.
Barratt ES: Impulsiveness and aggression; in Monahan J, Steadman HJ (eds): Violence and Mental Disorder: Developments in Risk Assessment. Chicago, University of Chicago Press, 1994, pp 61–79.
34.
Hilbe JM: Negative binomial regression. Cambridge, Cambridge University Press, 2007.
35.
Lenzenweger MF, Clarkin JF, Fertuck EA, Kernberg OF: Executive neurocognitive functioning and neurobehavioral systems indicators in borderline personality disorder: a preliminary study. J Pers Disord 2004;18:421–438.
36.
Castaneda R, Lifshutz H, Galanter M, Medalia A, Franco H: Treatment compliance after detoxification among highly disadvantaged alcoholics. Am J Drug Alcohol Abuse 1992;18:223–234.
37.
Harris AH, McKellar JD, Moos RH, Schaefer JA, Cronkite RC: Predictors of engagement in continuing care following residential substance use disorder treatment. Drug Alcohol Depend 2006;84:93–101.
38.
Penades R, Catalan R, Pujol N, Puig O, Guarch J, Masana G, Navarro V, Gasto C: Is memory impairment a rate limiter in cognitive behavioural therapy for chronic schizophrenia? Psychother Psychosom 2010;79:129–130.
39.
Keilp JG, Sackeim HA, Brodsky BS, Oquendo MA, Malone KM, Mann JJ: Neuropsychological dysfunction in depressed suicide attempters. Am J Psychiatry 2001;158:735–741.
40.
Ogrodniczuk JS: New directions in treatment research for personality disorders: effectiveness of different levels of care. Psychother Psychosom 2011;80:65–69.
41.
Bartak A, Andrea H, Spreeuwenberg MD, Ziegler UM, Dekker J, Rossum BV, Hamers EFM, Scholte W, Aerts J, Busschbach JJV, Verheul R, Stijnen T, Emmelkamp PMG: Effectiveness of outpatient, day hospital, and inpatient psychotherapeutic treatment for patients with cluster B personality disorders. Psychother Psychosom 2011;80:28–38.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.